Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cardinal HealthLTS:0HTG +0.71%86 3-Year EBITDA Growth Rate is 38.80% as of Jun. 2026, which is 351% above its 10-year median of 8.60. GuruFocus rates LTS:0HTG with a GF Score™ of 86/100 and a GF Value™ of $150.74 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 105 Medical Distribution companies, Cardinal Health ranks better than 86.67% on this metric.
During the past 12 months, Cardinal Health's average EBITDA Per Share Growth Rate was 14.30% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 38.80% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 71.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Cardinal Health was 302.40% per year. The lowest was -73.10% per year. And the median was 8.60% per year.
Cardinal Health (LTS:0HTG) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Cardinal Health 3-Year EBITDA Growth Rate Related Terms
LTS:0HTG vs COR, HSIC, MCK: 3-Year EBITDA Growth Rate Comparison
For the Medical Distribution subindustry, Cardinal Health's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cardinal Health 3-Year EBITDA Growth Rate vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Cardinal Health's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Cardinal Health's 3-Year EBITDA Growth Rate falls into.
Cardinal Health 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 38.80% mean?
Cardinal Health (LTS:0HTG) has a 3-Year EBITDA Growth Rate of 38.80% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Cardinal Health and its competitors. This is 351% above median its historical median of 8.60. According to the industry distribution chart, Cardinal Health ranks #14 out of 105 companies in the Medical Distribution industry, placing it in the top 13.3%.
Is Cardinal Health's 3-Year EBITDA Growth Rate too high?
Cardinal Health's current 3-Year EBITDA Growth Rate of 38.80% is 351% above median its 10-year median of 8.60. The Medical Distribution industry median 3-Year EBITDA Growth Rate is 5.40. Cardinal Health's value of 38.80% is 618.5% above this industry median. Based on the distribution chart, Cardinal Health ranks #14 out of 105 companies in the Medical Distribution industry, which is in the top quartile — a strong position relative to peers. Overall, Cardinal Health has a GF Score™ of 86/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cardinal Health's 3-Year EBITDA Growth Rate compare to COR and HSIC?
According to the Medical Distribution industry distribution chart, Cardinal Health ranks #14 out of 105 companies for 3-Year EBITDA Growth Rate. This places Cardinal Health in the top 13% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 5.40. Cardinal Health's value of 38.80% is 618.5% above this benchmark. While the company's 10-year median is 8.60 vs. the industry median of 5.40, Cardinal Health has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Distribution company?
The median 3-Year EBITDA Growth Rate among Medical Distribution companies is 5.40, based on 105 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cardinal Health's current 3-Year EBITDA Growth Rate of 38.80% is 618.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Cardinal Health and its competitors. For the Medical Distribution industry, the median 3-Year EBITDA Growth Rate is 5.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cardinal Health's current 3-Year EBITDA Growth Rate is 38.80%, which is 351% above median its own 10-year median of 8.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cardinal Health stock overvalued right now?
Based on GuruFocus' analysis, Cardinal Health (LTS:0HTG) is currently considered Significantly Overvalued. The stock's GF Value™ is $150.74, compared to a current price of $237.07 — trading 57.3% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 38.80%, which is 351% above median its 10-year median of 8.60 and 618.5% above the Medical Distribution industry median of 5.40. Cardinal Health's overall GF Score™ is 86/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Cardinal Health (LTS:0HTG), the current 3-Year EBITDA Growth Rate is 38.80% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cardinal Health (LTS:0HTG) Overvalued in 2026?
Based on GuruFocus' analysis, Cardinal Health stock appears to be overvalued.
The current stock price of $237.07 is trading 57.3% above its estimated GF Value™ of $150.74.
GuruFocus considers Cardinal Health to be Significantly Overvalued.
Key valuation signals for LTS:0HTG:
3-Year EBITDA Growth Rate: 38.80% (351% above median its 10-year median of 8.60)
GF Value™: $150.74 vs. price of $237.07 (57.3% above fair value)
Industry Position: 618.5% above the Medical Distribution median (#14 of 105)
No single metric tells the full story. See the LTS:0HTG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cardinal Health is one of three leading pharmaceutical wholesalers in the US, engaged in sourcing and distributing of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. Cardinal, Cencora, and McKesson hold well over 90% of the US pharmaceutical wholesale industry. Cardinal Health also supplies medical-surgical products and equipment to healthcare facilities in North America, Europe, and Asia.
86GF Score
Get the complete analysis for LTS:0HTG
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0HTG has been successfully added to your 
